BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Jade Biosciences\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Jade Biosciences\, Inc.'s drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07541287-10888@assetmemo.bio
DTSTAMP:20261121T005926Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:JADE101: Phase 2 readout est. (NCT07541287)
DESCRIPTION:JADE101\, phase 2\, IgA Nephropathy.\nStudy: A Study of JADE101
  in Participants With Immunoglobulin A Nephropathy\nEstimated primary comp
 letion: January 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /jade101#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07541287
URL:https://assetmemo.bio/drug/jade101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902817-10888@assetmemo.bio
DTSTAMP:20261121T005926Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:JADE101: Phase 3 readout est. (NCT07902817)
DESCRIPTION:JADE101\, phase 3\, IgA Nephropathy.\nStudy: A Phase 3 Blinded 
 Study of JADE101 in Participants With Immunoglobulin A Nephropathy\nEstima
 ted primary completion: June 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/jade101#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07902817
URL:https://assetmemo.bio/drug/jade101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
